12 Best Genomic Stocks to Buy Now
In this article, we present to you the 12 best genomic stocks to buy now according to hedge funds.
Posts Tagged ‘Biomarin Pharmaceutical Inc (BMRN)’
12 Best Large Biotech Stocks to Buy Now
Biotech companies are research science-driven companies focusing on novel drug development and clinical research with aims to treat diseases and medical conditions.
Hedge Fund and Insider Trading News: Steven A Cohen, Crispin Odey, Ray Dalio, Warren Buffett, Adrigo Hedge, iMedia Brands Inc (IMBI), Estee Lauder Companies Inc (EL), and More
The $400 billion corner of quant investing known as risk parity has a history of doubt and division, and Bridgewater Associates has started a new chapter.
Catalyst Pharmaceuticals Inc (CPRX) Isn’t Out Of The Woods With Firdapse Just Yet
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) just announced that it is carrying forward with a special protocol assessment (SPA) for its lead asset, Firdapse, for the treatment ...
10 Most Successful Innovative Companies in The World in 2016
Bringing something new to the table is something that seems to be difficult these days, considering that many things have already been done, have already been invented, and have...
A Look At The Science Behind BioMarin Pharmaceutical Inc. (BMRN)’s Next Pivotal Candidate
BioMarin Pharmaceutical Inc.
Blue Jay Capital Betting On Big Returns From These Healthcare Stocks
Founded by Paul Sinclair in August 2014, Blue Jay Capital Management is a healthcare-focused hedge fund based in California.
BioMarin Pharmaceutical Inc. (BMRN)’s Setback Isn’t Really A Setback
BioMarin Pharmaceutical Inc.
Thursday’s Top Trending Tickers: MSFT, VOD, LB, BMRN, GLW
The U.S stock market is green across the board as positive reigns ahead of crucial jobs data to be announced tomorrow.
Why Traders Are Buzzing About MGM, Apple, and Three Other Companies Today
Although crude futures are well in the green, the three indexes have opened in the red on Friday. The Dow and S&P 500 are off by 0.2% while the NASDAQ index has lost around 0...
Mariner Investment’s Top Healthcare Picks
Among some 800 hedge funds we track at Insider Monkey, we seldom come across funds that specialize in investing in a particular sector or have a penchant for investing in companies...
Palo Alto’s Top Picks for This Year Following Impressive 2015 Returns
William Leland Edwards' Palo Alto Investors has about $2.22 billion worth of regulatory assets under its management.
Top Stock Picks of Multi-Billion Dollar, Healthcare-Focused Fund Palo Alto Investors
Palo Alto Investors, founded by Wall Street veteran William Leland Edwards in 1989, is one of the biggest healthcare investment shops in the United States, with over $2 billion...
New Additions Highlight Kyle Bass’ Top Stock Picks for Q4
Kyle Bass of Hayman Advisors is one investment manager with great cachet, which includes having a chapter dedicated to him in Michael Lewis' post 2007-08 financial crises book...
BioMarin Pharmaceutical Inc. (BMRN) Surges But Is It A Good Stock To Buy Now?
Is BioMarin Pharmaceutical Inc.
Endo International plc (ENDP), BioMarin Pharmaceutical Inc. (BMRN): Visium Picks Returned 13% but Net Returns Were Only 5% – Here’s Why
The broad portfolio of Jacob Gottlieb’s Visium Asset Management enjoyed a very strong quarter, with the weighted average returns of its 817 reported positions in companies with...
Billionaire John Griffin’s Five Picks That Killed the Market This Quarter
John Griffin’s Blue Ridge Capital had a great start to the year, as its 45 long positions in stocks with a market cap above $1.0 billion returned 6.8% in the first quarter.
Era Group Inc (ERA), BioMarin Pharmaceutical Inc. (BMRN), & Assured Guaranty Ltd. (AGO) Among Stocks Amici Capital Is Bullish on
Paul Orlin's Amici Capital has increased its exposure to Era Group Inc (NYSE:ERA), as a new filing with the Securities and Exchange Commission shows.
Palo Alto Rejoicing at ABIOMED, Inc. (ABMD)’s 18% Spike
ABIOMED, Inc. (NASDAQ:ABMD) spiked as high as 21% in Tuesday's intraday trading to eventually close at 18% in the green at $72.48.
BioMarin Pharmaceutical Inc. (BMRN) and Other Top New Picks of Healthcare-Focused Visium Asset Management
Jacob Gottlieb's Visium Asset Management has recently revealed its equity positions as of the end of the fourth quarter in a 13F filing with the Securities and Exchange Commission...
Tang Capital Management Discloses Moves into La Jolla Pharmaceutical Company (LJPCD), Vanda Pharmaceuticals Inc. (VNDA), Mirati Therapeutics Inc. (MRTX) & Others
Tang Capital Management, led by Kevin C. Tang, revealed in a filing several moves that have impacted its equity portfolio.
Should You Buy Regeneron Pharmaceuticals Inc (REGN)?
If you were to ask many investors, hedge funds are viewed as delayed, outdated investment vehicles of an era lost to time.
AstraZeneca plc (ADR) (AZN), Bristol-Myers Squibb Co (BMY), BioMarin Pharmaceutical Inc. (BMRN): Three PDUFA Dates That Will Kick Off 2014
The phrase "PDUFA date" is thrown around frequently when discussing biotech and pharma companies.
What Hedge Funds Think About Vertex Pharmaceuticals Incorporated (VRTX)
In the 21st century investor’s toolkit, there are tons of metrics market participants can use to track the equity markets.
Onyx Pharmaceuticals, Inc. (ONXX) Investors: Listen Up
In the 21st century investor’s toolkit, there are tons of metrics shareholders can use to track publicly traded companies.
Do Hedge Funds and Insiders Love Alexion Pharmaceuticals, Inc. (ALXN)?
In the 21st century investor’s toolkit, there are dozens of indicators investors can use to analyze Mr. Market.
Hedge Funds Are Crazy About BioMarin Pharmaceutical Inc. (BMRN)
In the financial world, there are dozens of gauges shareholders can use to analyze stocks. Two of the most under-the-radar are hedge fund and insider trading sentiment.
Is Illumina, Inc. (ILMN) Going to Burn These Hedge Funds?
If you were to ask many investors, hedge funds are assumed to be useless, old investment tools of a period lost to current times.
Incyte Corporation (INCY), BioMarin Pharmaceutical Inc. (BMRN): Two Biotech Stocks That Could Be on Novartis AG (ADR) (NVS)’s Buyout Radar
The buyout drama surrounding cancer drug maker Onyx Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. (ALXN), BioMarin Pharmaceutical Inc. (BMRN): 5 of the World’s Most Ultra-Rare Diseases
There are few times when your doctor or physician will utter the phrase, "I don't know" to a patient, but when you're dealing with the rarest of diseases, then all bets are off...
Aegerion Pharmaceuticals, Inc. (AEGR), ISIS Pharmaceuticals, Inc. (ISIS), BioMarin Pharmaceutical Inc. (BMRN): Orphan Drug Makers – Robust Investment Opportunities
The US pharmaceutical industry has been revolutionized by the emerging biotech companies which have discovered new ways to cure even the rarest of diseases.
Alexion Pharmaceuticals, Inc. (ALXN), Eli Lilly & Co. (LLY): Five Drugmakers With a Lot on the Line
You may or may not have heard, but it's earnings season again.
Exploding Pipeline Makes BioMarin Pharmaceutical Inc. (BMRN) Attractive Takeover Target
The Orphan Drug pipeline of BioMarin Pharmaceutical Inc.
LinkedIn Corp (LNKD), BioMarin Pharmaceutical Inc. (BMRN), ArcelorMittal (ADR) (MT): Don’t Miss These Three Companies With High Earnings-Per-Share Forecasts
Earnings per share, or EPS, is an important metric for investors performs a lot of functions: It helps suggest potential profits on individual shares in a company.
Wells Fargo & Co (WFC), Baxter International Inc. (BAX): Obamacare-Inspired Investment Opportunities
Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape.
Dendreon Corporation (DNDN), Johnson & Johnson (JNJ), Medivation Inc (MDVN): The Most Expensive Drugs in the World
The prescription-drug market currently generates a whopping $950 billion in annual sales, and that figure is likely to grow to $1.2 trillion by 2016.
Alexion Pharmaceuticals, Inc. (ALXN), BioMarin Pharmaceutical Inc. (BMRN): What Makes a Good Orphan Drug Investment?
The word “Orphan’ in biotechnology creates excitement! It means that a company has more years of exclusivity on a product and it also indicates that a company’s technology...
Highlights from the Goldman Sachs Group Inc (GS) Healthcare Conference
Healthcare was considered a defensive sector during the 2008–09 recession, but I believe it will continue to perform going forward.
Clovis Oncology Inc (CLVS), Synta Pharmaceuticals Corp. (SNTA): Post-ASCO Movers – Are Any a Buy?
Late last year, Clovis Oncology Inc (NASDAQ:CLVS) saw its share price cut in half, to $11.50, after reporting that its Phase 3 drug CO-101 failed to show a benefit over chemotherapy...
Clovis Oncology Inc (CLVS): Double Data, Double Stock Price
Plenty of data was presented at the American Society for Clinical Oncology meeting over the weekend, causing the first set of ASCO pops, but Clovis Oncology Inc (NASDAQ:CLVS) ...
Hedge Funds Are Selling BioMarin Pharmaceutical Inc. (BMRN)
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was in 22 hedge funds' portfolio at the end of the first quarter of 2013.
Alexion Pharmaceuticals, Inc. (ALXN), Vertex Pharmaceuticals Incorporated (VRTX): Orphan Drug Biotechs Do It Best
There are many biotech stocks to choose from that have long-lasting value.
Analyst Roundtable: Any Surprises in Amarin Corporation plc (ADR) (AMRN)’s Fourth Quarter?
Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to discuss Amarin Corporation plc (ADR) (NASDAQ:AMRN) , a biotech that recently launched...
4 Orphan Drugs Making Waves in 2013: Sanofi SA (ADR) (SNY) and More
Orphan drugs -- medications meant for small patient populations with rare, dangerous diseases -- can be a rewarding business for biotech firms that strike gold.
BioMarin Pharmaceutical Inc. (BMRN) Earnings: An Early Look
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
BioMarin Pharmaceutical Inc. (BMRN) is a Prime Takeover Target
How many of us as investors want to identify companies that are pioneers in their industry? Is it possible to find commonality across sectors, which factors make specific companies...
